Brown Advisory Inc. held its position in Novavax Inc. (NASDAQ:NVAX) during the second quarter, according to its most recent filing with the SEC. The firm owned 93,775 shares of the biopharmaceutical company’s stock at the end of the second quarter. Brown Advisory Inc.’s holdings in Novavax were worth $682,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP boosted its position in Novavax by 43.4% in the first quarter. Wellington Management Group LLP now owns 12,711,938 shares of the biopharmaceutical company’s stock valued at $65,593,000 after buying an additional 3,849,585 shares in the last quarter. State Street Corp boosted its position in Novavax by 40.1% in the first quarter. State Street Corp now owns 12,320,840 shares of the biopharmaceutical company’s stock valued at $63,579,000 after buying an additional 3,527,714 shares in the last quarter. Deerfield Management Co. acquired a new position in Novavax during the first quarter valued at $12,674,000. Franklin Resources Inc. boosted its position in Novavax by 71.8% in the first quarter. Franklin Resources Inc. now owns 5,226,565 shares of the biopharmaceutical company’s stock valued at $26,969,000 after buying an additional 2,183,700 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Novavax by 9,162.1% in the first quarter. JPMorgan Chase & Co. now owns 1,316,238 shares of the biopharmaceutical company’s stock valued at $6,792,000 after buying an additional 1,302,027 shares in the last quarter. Hedge funds and other institutional investors own 79.84% of the company’s stock.
Novavax Inc. (NASDAQ:NVAX) traded down 0.97% during mid-day trading on Friday, reaching $2.04. The company’s stock had a trading volume of 7,128,962 shares. Novavax Inc. has a one year low of $1.16 and a one year high of $9.23. The company’s market capitalization is $552.50 million. The stock has a 50-day moving average price of $5.79 and a 200-day moving average price of $6.03.
Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $8.03 million. Novavax had a negative return on equity of 112.45% and a negative net margin of 1,405.84%. The company’s revenue for the quarter was down 82.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. Equities research analysts forecast that Novavax Inc. will post ($1.09) EPS for the current year.
Several research analysts have recently weighed in on NVAX shares. Piper Jaffray Cos. restated an “overweight” rating and issued a $14.00 price target on shares of Novavax in a research note on Friday, September 9th. Vetr cut Novavax from a “strong-buy” rating to a “buy” rating and set a $7.86 price objective for the company. in a research report on Monday, August 15th. Wedbush reiterated an “outperform” rating and set a $14.00 price objective on shares of Novavax in a research report on Wednesday, July 27th. Zacks Investment Research upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Wednesday, September 21st. Finally, FBR & Co set a $17.00 price objective on Novavax and gave the company a “buy” rating in a research report on Thursday, August 11th. Seven analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.06.
In other news, Director Gail Boudreaux purchased 100,000 shares of Novavax stock in a transaction dated Tuesday, September 20th. The shares were purchased at an average price of $1.45 per share, with a total value of $145,000.00. Following the transaction, the director now owns 200,000 shares in the company, valued at $290,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael A. Mcmanus, Jr. purchased 30,000 shares of Novavax stock in a transaction dated Wednesday, September 21st. The shares were purchased at an average cost of $1.61 per share, for a total transaction of $48,300.00. Following the transaction, the director now owns 247,590 shares in the company, valued at approximately $398,619.90. The disclosure for this purchase can be found here. Insiders own 3.50% of the company’s stock.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax Inc. (NASDAQ:NVAX).
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.